| Title |
Maintenance of nutritional status in patients with cystic fibrosis: new and emerging therapies
|
|---|---|
| Published in |
Drug Design, Development and Therapy, June 2012
|
| DOI | 10.2147/dddt.s9258 |
| Pubmed ID | |
| Authors |
Daina Kalnins, Michael Wilschanski |
| Abstract |
Poor clinical outcomes in cystic fibrosis are often associated with undernutrition. Normal growth and development should be achieved in cystic fibrosis, and nutritional counseling is paramount at all ages. Prevention and early detection of growth failure is the key to successful nutritional intervention. The advance in nutritional management is certainly one factor that has contributed to the improved survival in recent decades. This review outlines the major nutritional parameters in the management of the patient with cystic fibrosis, including recent advances in pancreatic enzyme replacement therapy and fat-soluble vitamin therapy. There are sections on complicated clinical situations which directly affect nutrition, for example, before and after lung transplantation, cystic fibrosis-related diabetes, and bone health. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | <1% |
| India | 1 | <1% |
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 117 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 16% |
| Student > Ph. D. Student | 16 | 13% |
| Researcher | 15 | 12% |
| Student > Master | 14 | 11% |
| Student > Postgraduate | 9 | 7% |
| Other | 25 | 20% |
| Unknown | 23 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 36% |
| Agricultural and Biological Sciences | 14 | 11% |
| Nursing and Health Professions | 8 | 7% |
| Biochemistry, Genetics and Molecular Biology | 8 | 7% |
| Chemistry | 4 | 3% |
| Other | 15 | 12% |
| Unknown | 29 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2012.
All research outputs
#20,657,128
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#1,437
of 2,268 outputs
Outputs of similar age
#139,924
of 179,215 outputs
Outputs of similar age from Drug Design, Development and Therapy
#6
of 7 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,215 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.